books on kindle

Sunday, July 12, 2020

Why won't Harper's Magazine allow ads for this book?

Does the Joseph Fair mystery suggest that Covid-19 might not be caused by SARS-CoV-2? Is it just a biomarker?


The doctor announced earlier this week that his Covid-19 antibody test had returned negative and that his “suspected” illness from the virus remains an “undiagnosed mystery.”

“I had myriad Covid symptoms, was hospitalized in a Covid ward & treated for Covid-related co-morbidities,” he tweeted in his defense.



Friday, July 10, 2020

Thursday, July 09, 2020

Malpractice? Ventilators may have killed many Covid-19 patients.


Covid-19 and Medicine’s Misguided Romance With Machines


The history of a controversial syndrome linked to Covid-19 shows the risks of letting technology dictate treatment.



https://undark.org/2020/07/09/covid-19-medicine-and-machines/


Fauci's pet drug Remdesivir causes kidney damage in some patients







Wednesday, July 08, 2020

Isn't it time to start treating Chronic Fatigue Syndrome like the viral illness it is?


Dr. Theodore Henderson: Treating CFS/ME as though it is caused by a virus
"Not surprisingly, those who have made a leap in their thinking about CFS/ME have found that treating it like a viral illness yields some success. Lerner and colleagues showed that treatment with the antiviral valacyclovir reduced symptoms of CFS/ME, as well as antibody titers and cardiac symptoms. Montoya and colleagues found that elevated antibody titers of EBV and HHV6 among patients with CFS/ME predicted a positive response to the antiviral valgancyclovir.9 In my own clinic, I have treated hundreds of patients with antivirals and found about 70% of the cases improve."
Source:
https://www.neurologyadvisor.com/topics/general-neurology/chronic-fatigue-syndrome-viruses-and-the-innate-immune-system/

Are we one step closer to the recognition that HHV-6 is the key to Chronic Fatigue Syndrome, AIDS, Alzheimer's and the autism epidemic?





"In 2018, a landmark paper examining samples of tissue from a brain bank for evidence of HHV6 infection gave ammunition to end that argument. Among the control sample, 22% had HHV6 protein and a larger percentage had HHV6 DNA in neurons. In contrast, among cases with depression, 73% of the cases had HHV6 protein and 87% had HHV6 DNA in neurons. Prusty and colleagues shook the ground with this paper. Not only did they find proteins of HHV6 inside brain cells, but confirmed the presence of the virus by a second set of distinct antibodies of different proteins, direct visualization using electron microscopy, and amplification and identification of the DNA of HHV6 inside the neurons of the same brains."
https://www.neurologyadvisor.com/topics/general-neurology/chronic-fatigue-syndrome-viruses-and-the-innate-immune-system/


Want to know the whole controversial history of HHV-6? Read this epic narrative.

Tuesday, July 07, 2020

Robert F. Kennedy Jr. on the Fauci book.

"Hot off the Press: You might want to read this . . ."
---Robert F. Kennedy. Jr.


https://www.instagram.com/p/B-xNfZSnNCg/

A Letter on Justice and Open Debate

"The free exchange of information and ideas, the lifeblood of a liberal society, is daily becoming more constricted. While we have come to expect this on the radical right, censoriousness is also spreading more widely in our culture: an intolerance of opposing views, a vogue for public shaming and ostracism, and the tendency to dissolve complex policy issues in a blinding moral certainty. We uphold the value of robust and even caustic counter-speech from all quarters. But it is now all too common to hear calls for swift and severe retribution in response to perceived transgressions of speech and thought. More troubling still, institutional leaders, in a spirit of panicked damage control, are delivering hasty and disproportionate punishments instead of considered reforms. Editors are fired for running controversial pieces; books are withdrawn for alleged inauthenticity; journalists are barred from writing on certain topics; professors are investigated for quoting works of literature in class; a researcher is fired for circulating a peer-reviewed academic study; and the heads of organizations are ousted for what are sometimes just clumsy mistakes. Whatever the arguments around each particular incident, the result has been to steadily narrow the boundaries of what can be said without the threat of reprisal. We are already paying the price in greater risk aversion among writers, artists, and journalists who fear for their livelihoods if they depart from the consensus, or even lack sufficient zeal in agreement."

https://harpers.org/a-letter-on-justice-and-open-debate/

Nutritional physician,invoking the Bible:: "Handling Pig Meat and Carcasses Greatly Increases the Spread of COVID-19"




"The disease, which has devastated the world, likely originated in industrially-raised, highly contaminated vaccinated pigs. Already, it has broken out in large numbers in two Chinese meat markets which specialize in this industrial fair and when an untold tonnage of pork was in the facilities. The sickened in many cases either at the pork flesh or were handling it.
In the latest the meat and seafood trading sections at Beijing’s huge wholesale market were found to be seriously contaminated with the coronavirus that causes COVID-19. The take-away is that it is in the farm-raised flesh that is the source of the tainting, especially the pigs, and it always as been. Yet, it appears that this has been covered-up."
Source:
https://cassingram.com/cutting-up-pig-carcasses-greatly-increases-the-spread-of-covid-19/

Bhupesh Prusty announces he has "several breakthrough results in hand"






Thanks to Bhupesh Prusty, the search for the cause of Chronic Fatigue Syndrome may soon be over.

Has Bhupesh Prusty found a promising treatment for HHV-6 and Chronic Fatigue Syndrome?

The Chronic Fatigue Syndrome and HHV-6 Scientist of the Year 

Dr. Bhupesh Prusty and Professor Thomas Rudel discuss their HHV-6 research

Will Bhupesh Prusty add more evidence that HHV-6 is the cause of Chronic Fatigue Syndrome?

"Bhupesh Prusty is determining if HHV-6 infections are hampering mitochondrial functioning in ME/CFS."

Chronic Fatigue Syndrome activist's 2018 research summary leaves out HHV-6 and the work of Bhupesh Prusty


The Chronic Fatigue Syndrome and HHV-6 Scientist of the Year 

Meet the scientist who may prove that HHV-6 is the Chronic Fatigue Syndrome virus


Why is the Chronic Fatigue Syndrome community ignoring the biggest breakthrough? 

Breaking news about Dr. Prusty's game-changing HHV-6 & Chronic Fatigue Syndrome research from the University of Wurzburg 

The major Chronic Fatigue Syndrome organization is supporting the scientist who may show HHV-6 is the cause of Chronic Fatigue Syndrome. 


The Prusty study of HHV-6 in Chronic Fatigue Syndrome that Solve ME/CFS supported.

Does the research of Bhupesh Prusty support the theory that HHV-6 is causing oxidative stress in AIDS & CFS?

If Bhupesh Prusty wins a Nobel Prize for proving HHV-6 is the cause of Chronic Fatigue Syndrome, will he share it with Gallo or Beldekas?

Chronic Fatigue Syndrome patients are finally discovering Prusty's CFS and HHV-6 research  



News story notes that one theory links Covid-19 to pigs.



https://timesofindia.indiatimes.com/india/peta-urges-authorities-to-close-live-animal-meat-markets-in-india/articleshow/76819677.cms


Monday, July 06, 2020

If the CDC had called AIDS "HHV-6 Disease" Chronic Fatigue Syndrome would not still be a mystery and there would be a treatment.

Dharam Ablashi on HHV-6:









"HHV-6 is actually likely to reduce HIV patient survival by accelerating the depletion of CD4 and CD8 T cells. HHV-6A was shown to accelerate AIDS progression in macaques.  Macaques co-infected with simian HIV and HHV-6A died quickly and showed a dramatic depletion in both CD4+ and CD8+ T cells, whereas those infected with only simian HIV never progressed to full blown AIDS."

 "We believe that infections are the most logical explanation for the inflammation neurodegeneration associated with Alzheimer’s, but don’t believe that there is a single pathogen responsible. HHV-6A and HHV-7 were identified as likely culprits in 2018 paper, using RNAseq analysis by Readhead and team. Two subsequent studies did not find an increase in HHV-6/7 using the same data, but at the same time did not find a significant presence of ANY herpesviruses in the brain, which we know is not the case. Dozens of careful studies have identified a high prevalence of low-level HHV-6 and HSV1 DNA in brain tissues. This tells us that RNAseq and ddPCR methods employed to date are not sufficiently sensitive to really answer the question of whether these viruses play a role in Alzheimer’s. Future studies should be done with both extremely sensitive assay as well as multiple samples from each brain region to answer the question of HHV-6A/B prevalence in Alzheimer’s samples vs. controls. In 2002, Ruth Itzhaki’s group looked for HHV-6 and HSV1 by nested PCR and found HHV-6 DNA in 70% of Alzheimer’s brains vs. 40% of controls. They found HSV1 at high levels in both AD patients and controls. Old-fashioned nested PCR is time-consuming and complicated because measures must be taken to prevent contamination, but this old-school technique may still be a better approach than newer techniques (such as RNAseq analyses) that can find little to no herpesvirus in these brains. The other issue is that infections may be early triggering events that disappear over time. It will take a lot of time and a solid investment in research to find any answers."

"We don’t think ME/CFS is triggered by a single pathogen; we believe it can be triggered by a number of intracellular pathogens including enterovirus, parvovirus B-19, mycoplasma pneumonia, chlamydia pneumonia, EBV, Cytomegalovirus (CMV), and HHV-6A/B and HHV-7. After the Dan Peterson and Paul Cheney first discovered HHV-6 in patients with the outbreak of ME/CFS in Incline Village Nevada in the 1980s, Dan Peterson, Anthony Komaroff, and Deidra Buchwald came to see Dr. Gallo to discuss whether HHV-6 played a role in ME/CFS.  At their request, we tested the antibodies of sera or plasma from ME/CFS patients.  During this process we found a subset of samples with very high antibody titers to HHV-6.  Buchwald, Komaroff, and associates published a paper in 1992 that found used primary cell culture to determine that 70% of ME/CFS patients but only 20% of controls showed signs of active replication.  Later in 2001, I published another paper that showed an increased level of IgM antibodies to an HHV-6 early antigen protein in ME/CFS patients. This was an assay based on a reagent produced at Gary Pearson’s lab at Georgetown, and unfortunately, this reagent is no longer available. Recently Dr. Bhupesh Prusty in Germany has shown how persistent HHV-6 infection can cause mitochondrial dysfunction, which may play a role in ME/CFS.  Also, Dr. Kondo recently published very interesting data showing that a neurovirulent HHV6 latency protein plays a pathogenic role in both depression and fatigue. He previously determined that HHV-6 builds up in the saliva when the body is fatigued and says this virus finds its way to the nasal passages and then on to the olfactory bulb and brain. A latency protein he calls SITH-1 then causes hyperactivation of the HPA axis and subsequent depression and fatigue."

Source:
http://microbeminded.com/2020/06/28/interview-with-dharam-ablashi-on-the-discovery-of-hhv6-and-its-involvement-in-chronic-inflammatory-disease/

How come nobody ever talks about HHV-6 as a "ticking time bomb"????

Dharam Ablashi on the nonepidemic of HHV-6:









"HHV-6 is actually likely to reduce HIV patient survival by accelerating the depletion of CD4 and CD8 T cells. HHV-6A was shown to accelerate AIDS progression in macaques.  Macaques co-infected with simian HIV and HHV-6A died quickly and showed a dramatic depletion in both CD4+ and CD8+ T cells, whereas those infected with only simian HIV never progressed to full blown AIDS."

 "We believe that infections are the most logical explanation for the inflammation neurodegeneration associated with Alzheimer’s, but don’t believe that there is a single pathogen responsible. HHV-6A and HHV-7 were identified as likely culprits in 2018 paper, using RNAseq analysis by Readhead and team. Two subsequent studies did not find an increase in HHV-6/7 using the same data, but at the same time did not find a significant presence of ANY herpesviruses in the brain, which we know is not the case. Dozens of careful studies have identified a high prevalence of low-level HHV-6 and HSV1 DNA in brain tissues. This tells us that RNAseq and ddPCR methods employed to date are not sufficiently sensitive to really answer the question of whether these viruses play a role in Alzheimer’s. Future studies should be done with both extremely sensitive assay as well as multiple samples from each brain region to answer the question of HHV-6A/B prevalence in Alzheimer’s samples vs. controls. In 2002, Ruth Itzhaki’s group looked for HHV-6 and HSV1 by nested PCR and found HHV-6 DNA in 70% of Alzheimer’s brains vs. 40% of controls. They found HSV1 at high levels in both AD patients and controls. Old-fashioned nested PCR is time-consuming and complicated because measures must be taken to prevent contamination, but this old-school technique may still be a better approach than newer techniques (such as RNAseq analyses) that can find little to no herpesvirus in these brains. The other issue is that infections may be early triggering events that disappear over time. It will take a lot of time and a solid investment in research to find any answers."

"We don’t think ME/CFS is triggered by a single pathogen; we believe it can be triggered by a number of intracellular pathogens including enterovirus, parvovirus B-19, mycoplasma pneumonia, chlamydia pneumonia, EBV, Cytomegalovirus (CMV), and HHV-6A/B and HHV-7. After the Dan Peterson and Paul Cheney first discovered HHV-6 in patients with the outbreak of ME/CFS in Incline Village Nevada in the 1980s, Dan Peterson, Anthony Komaroff, and Deidra Buchwald came to see Dr. Gallo to discuss whether HHV-6 played a role in ME/CFS.  At their request, we tested the antibodies of sera or plasma from ME/CFS patients.  During this process we found a subset of samples with very high antibody titers to HHV-6.  Buchwald, Komaroff, and associates published a paper in 1992 that found used primary cell culture to determine that 70% of ME/CFS patients but only 20% of controls showed signs of active replication.  Later in 2001, I published another paper that showed an increased level of IgM antibodies to an HHV-6 early antigen protein in ME/CFS patients. This was an assay based on a reagent produced at Gary Pearson’s lab at Georgetown, and unfortunately, this reagent is no longer available. Recently Dr. Bhupesh Prusty in Germany has shown how persistent HHV-6 infection can cause mitochondrial dysfunction, which may play a role in ME/CFS.  Also, Dr. Kondo recently published very interesting data showing that a neurovirulent HHV6 latency protein plays a pathogenic role in both depression and fatigue. He previously determined that HHV-6 builds up in the saliva when the body is fatigued and says this virus finds its way to the nasal passages and then on to the olfactory bulb and brain. A latency protein he calls SITH-1 then causes hyperactivation of the HPA axis and subsequent depression and fatigue."

Source:
http://microbeminded.com/2020/06/28/interview-with-dharam-ablashi-on-the-discovery-of-hhv6-and-its-involvement-in-chronic-inflammatory-disease/

Chronic Fatigue Syndrome and AIDS drug Ampligen to be used as possible vaccine adjuvant for Covid-19



AIM ImmunoTech Signs Material Transfer and Research Agreement with Japan's National Institute of Infectious Diseases and Shionogi, a Leading Global Pharmaceutical Company, to Test Ampligen as Potential Vaccine Adjuvant for COVID-19


Monday, July 6, 2020 9:00 AM EST

OCALA, FL / ACCESSWIRE / July 6, 2020 / AIM ImmunoTech (NYSE American:AIM), today announced that is has signed a material transfer and research agreement with Japan's National Institute of Infectious Diseases (NIID) and Shionogi & Co., Ltd. (Shionogi), a leading global pharmaceutical company headquartered in Japan, in order to test AIM's drug Ampligen as a potential adjuvant therapy for COVID-19, the new coronavirus infectious disease caused by SARS-CoV-2. Under the agreement, AIM will provide Ampligen samples for various research projects. The details of all preclinical and clinical results will remain confidential until released by NIID and Shionogi.
This program will be a collaboration between NIID and Shionogi, with AIM supplying the Ampligen. Hideki Hasegawa, MD, PhD, Director of the NIID's Influenza Virus Research Center, and Director of the World Health Organization (WHO) Collaborating Centre for Reference and Research on Influenza, Tokyo is a world-class expert on viral vaccines and Shionogi has been committed to infectious diseases for more than 60 years as their key focus.
Tom Equels, CEO of AIM ImmunoTech, commented, "We are honored to work with Japan's esteemed NIID, as well as Shionogi, one of the world's premier pharmaceutical companies, in order to accelerate the development of potential COVID-19 vaccines. I truly believe Dr. Hasegawa and the team at Shionogi are among the foremost experts in the field and ideal partners for this exciting collaboration. These new studies are specifically designed to explore Ampligen as a potential vaccine adjuvant. Prior U.S. National Institutes of Health-contracted animal experiments with Ampligen have demonstrated strong prophylactic antiviral activity against the earlier SARS-CoV-1 virus (100% protective survival vs. 100% mortality), which is quite similar to the SARS-CoV-2 virus that causes COVID-19. Prior NIID influenza studies also established Ampligen's strong potential as a viral vaccine adjuvant. We look forward to collaborating with NIID and Shionogi to determine whether Ampligen could be equally effective as a vaccine enhancer for the SARS-CoV-2 virus in combination with promising vaccine candidates."
About the National Institute of Infectious Diseases (NIID)
Japan's National Institute of Infectious Diseases aims to carry out extensive and original research projects on a variety of contagious diseases from the standpoint of preventive medicine, improving human health and welfare by suppressing infectious diseases, and clarifying and supporting the scientific background of health and medical administration of the government.
About Shionogi
Shionogi & Co., Ltd. is committed to "Protect people worldwide from the threat of infectious diseases." Shionogi is a Japanese pharmaceutical company known for developing Crestor, Tivicay and other successful pharmaceuticals. Dating back to 1878 and incorporated in 1919, the company is listed on the Tokyo Stock Exchange and is a constituent of the Nikkei 225 stock index. The company's areas of focus include infectious diseases, pain/CNS and cancer medicines.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat immune disorders, viral diseases and multiple types of cancers. AIM's flagship products include the Argentina-approved drug rintatolimod (trade names Ampligen® or Rintamod®) and the FDA-approved drug Alferon N Injection®. Based on results of published, peer-reviewed pre-clinical studies and clinical trials, AIM believes that Ampligen® may have broad-spectrum anti-viral and anti-cancer properties. Clinical trials of Ampligen® include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. These and other potential uses will require additional clinical trials to confirm the safety and effectiveness data necessary to support regulatory approval and additional funding. Rintatolimod is a double-stranded RNA being developed for globally important debilitating diseases and disorders of the immune system.
The Company is also advancing Ampligen® as a potential treatment for COVID-19, the disease caused by the SARS-CoV-2 coronavirus, and believes Ampligen® has significant therapeutic potential as both an early-onset treatment and prophylaxis against this new and deadly virus. The U.S. Food and Drug Administration has authorized the first human trial assessing the safety and effectiveness of Ampligen® in combination with interferon alfa-2b, in cancer patients with COVID-19.

Three Big Books

Two books on amazon

Everyone needs to know what the CDC is hiding about CFS and HHV-6. NEW YORK NATIVE contains both volumes of THE CHRONIC FATIGUE SYNDROME EPIDEMIC COVER-UP. The print version is $23. Only $7.98 in Kindle.

Popular Posts in the Last 7 Days

Our books on Amazon that are changing the way the world looks at CFS, HHV-6, and AIDS

Blog Archive

You can support us by listening to these songs by Charles Ortleb on Spotify.

Closing Argument Audible

African Swine Fever Novel Audible

Stonewall Audible